BTB Logo Master R4 rgbBTB Powered By MTPConnect logolockup

The Biomedical Translation Bridge program is an initiative of the Medical Research Future Fund, providing up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to the proof of concept stage.

The BTB program is operated by MTPConnect, in partnership with BioCurate (University of Melbourne and Monash University), UniQuest (University of Queensland through its drug discovery initiative QEDDI), the Medical Device Partnering Program (MDPP, led by Flinders University), and the Bridge and BridgeTech programs (Queensland University of Technology); all pre-eminent organisations engaged in the translation and commercialisation of health and medical research.

The MDPP's role is to assess and support eligible medical technology applications for funding, whilst BioCurate and UniQuest will together do the same for therapeutics. 

MedTech projects founded in Round 1 include:

  • Australian National University, Australian Capital Territory, is developing rapid and objective eye and brain testing for better management of ophthalmic and neurological diseases.
  • DBS Technologies Pty Ltd, Victoria, is developing an innovative device providing adaptive deep brain stimulation for people with Parkinson’s disease.
  • Noisy Guts Pty Ltd, Western Australia, has developed a non-invasive acoustic belt that uses artificial intelligence to decode gut noises to accurately diagnose and monitor common gut disorders such as Irritable Bowel Syndrome.
  • University of Melbourne’s Melbourne Dental School, Victoria, is progressing a novel dental implant to commercialisation.

For more information, contact MedTech Ventures Case Manager, This email address is being protected from spambots. You need JavaScript enabled to view it. or visit the BTB website where you can view the BTB guidelines.